No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents
出版年份 2016 全文链接
标题
No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume 15, Issue 12, Pages 1653-1659
出版商
Informa UK Limited
发表日期
2016-08-24
DOI
10.1080/14740338.2016.1228872
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Psoriasis and New-onset Depression: A Danish Nationwide Cohort Study
- (2016) P Jensen et al. ACTA DERMATO-VENEREOLOGICA
- Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort study
- (2016) A. Egeberg et al. BRITISH JOURNAL OF DERMATOLOGY
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Ixekizumab: First Global Approval
- (2016) Anthony Markham DRUGS
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States
- (2016) Melissa J. Danesh et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis
- (2016) Y. Umezawa et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab: First Global Approval
- (2015) Mark Sanford et al. DRUGS
- The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
- (2015) Florence J. Dalgard et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial
- (2015) M. Augustin et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug
- (2015) Charlie Schmidt NATURE BIOTECHNOLOGY
- Targeting the IL-17–TH17 pathway
- (2015) Hilary S. Bartlett et al. NATURE REVIEWS DRUG DISCOVERY
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial
- (2014) B. Zhu et al. BRITISH JOURNAL OF DERMATOLOGY
- The common inflammatory etiology of depression and cognitive impairment: a therapeutic target
- (2014) David J Allison et al. Journal of Neuroinflammation
- Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
- (2014) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammation: a mechanism of depression?
- (2014) Qiu-Qin Han et al. Neuroscience Bulletin
- Interleukin-17 inhibits Adult Hippocampal Neurogenesis
- (2014) Qiang Liu et al. Scientific Reports
- Poststroke Neuropsychiatric Symptoms: Relationships with IL-17 and Oxidative Stress
- (2014) W. Swardfager et al. Biomed Research International
- Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory
- (2013) K.B. Gordon et al. BRITISH JOURNAL OF DERMATOLOGY
- IL-17 targeted therapies for psoriasis
- (2013) Andrea Chiricozzi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Inflammatory T Helper 17 Cells Promote Depression-like Behavior in Mice
- (2012) Eléonore Beurel et al. BIOLOGICAL PSYCHIATRY
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
- (2012) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune system to brain signaling: Neuropsychopharmacological implications
- (2011) Lucile Capuron et al. PHARMACOLOGY & THERAPEUTICS
- The Risk of Depression, Anxiety, and Suicidality in Patients With Psoriasis
- (2010) CHOSIDOW OLIVIER et al. ARCHIVES OF DERMATOLOGY
- Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial
- (2010) Richard G. Langley et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
- (2009) Andrew H. Miller et al. BIOLOGICAL PSYCHIATRY
- An overview of IL-17 function and signaling
- (2008) Sarah L. Gaffen CYTOKINE
- Structure–function relationships in the IL-17 receptor: Implications for signal transduction and therapy
- (2008) Fang Shen et al. CYTOKINE
- From inflammation to sickness and depression: when the immune system subjugates the brain
- (2007) Robert Dantzer et al. NATURE REVIEWS NEUROSCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now